Ipca Laboratories Ltd

Ipca Laboratories Ltd Performance

Day's Price Range
52-Week Price Range
1 Month Return-4.52 %
3 Month Return-9.43 %
1 Year Return-21.02 %

Analyst Rating

based on 21 analysts


Based on 21 analysts offering long term price targets for Ipca Laboratories Ltd. An average target of ₹930.33

Source: S&P Global Market Intelligence

Analyst Forecast

Ipca Laboratories Ltd price forecast by 21 analysts

Upside of18.84%







Current Price: ₹784.75

Target Price: ₹930.33

Source: S&P Global Market Intelligence

Ipca Laboratories Ltd Price Movements

  • IPCA Labs sank 4% on 17 Feb, 2023

    IPCA Labs share price dipped to hit 52-week lows after the company reported a 45% yearly decline in net profits to Rs 108 crores.

Ipca Laboratories Ltd Valuation

Ipca Laboratories Ltd in the last 5 years

Lowest (18.72x)

October 10, 2019

Today (37.84x)

March 22, 2023

Highest (46.07x)

October 25, 2022



Price to Earnings TTM Ratio

Insights on Ipca Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    MF Holding Up

    Mutual Funds have increased holdings from 29.71% to 29.79% in Dec 2022 quarter

  • imgNO EFFECT

    Against Peers

    In the last 1 year, Dr Reddys Laboratories Ltd has given 8.4% return, outperforming this stock by 29.4%

  • imgNO EFFECT

    Against Peers

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 199.6% return, outperforming this stock by 185.1%

  • imgNO EFFECT

    Promoter Holding Unchanged

    Promoters holdings remained unchanged at 46.29% of holdings in Dec 2022 quarter


    Profit Down

    Netprofit is down for the last 2 quarters, 143.9Cr → 107.84Cr (in ₹), with an average decrease of 25.1% per quarter


    FII Holding Down

    Foreign Institutions have decreased holdings from 10.57% to 10.46% in Dec 2022 quarter


    Retail Holding Down

    Retail Investor have decreased holdings from 9.35% to 9.22% in Dec 2022 quarter


    Price Dip

    In the last 1 year, IPCALAB stock has moved down by -21.0%


    Revenue Fall

    Revenue is down for the last 2 quarters, 1.63KCr → 1.57KCr (in ₹), with an average decrease of 3.7% per quarter

Ipca Laboratories Ltd Shareholding Pattern

InvestorsHoldings %Prev. 4 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Ipca Laboratories Ltd Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Corporate Announcements

  • Ipca Laboratories Ltd Earnings Results

    Ipca Laboratories Ltd’s net profit fell -45.07% since last year same period to ₹107.84Cr in the Q3 2022-2023. On a quarterly growth basis, Ipca Laboratories Ltd has generated -25.06% fall in its net profits since last 3-months.

    Read More
  • Ipca Laboratories Ltd Dividends November,2022

    In the quarter ending December 2022, Ipca Laboratories Ltd has declared dividend of ₹4 - translating a dividend yield of 1.53%.

    Read More

Ipca Laboratories Ltd Company Information

Ipca Laboratories Limited IPCA was incorporated on 19th October 1949 under the name of The Indian Pharmaceutical Combine Association Limited. Ipca is a fully integrated pharmaceutical company manufacturing and marketing over 350 formulations and 80 APIs covering various therapeutic segments. The products of the Company are now sold in over 100 countries across the globe. The Company has 17 manufacturing units in India manufacturing APIs and formulations for the world market.Ipcas APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the USFood and Drug Administration FDA UKMedicines and Healthcare products Regulatory Agency MHRA South AfricaMedicines Control Council MCC BrazilBrazilian National Health Vigilance Agency ANVISA and AustraliaTherapeutic Goods Administration TGA with operations in over 100 countries. Ipca is one of the biggest manufacturers in the world of APIs Atenolol Antihypertensive Chloroquine Phosphate Antimalarial Furosemide Diuretic and Pyrantel Salts Anthelmintic right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to Ipca Laboratories Limited in 6th August of the year 1964 and again name was changed to Ipca Laboratories Private Limited in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears in the year 1969 at Mumbai. The present management took over the company in November of the year 1975. In the year 1976 started domestic marketing operations the first company to offer sugarcoated Chloroquine tablets. Launched formulations of Metoclopramide under brand name Perinorm for the first time in India during the year 1978. After two years in 1980 the company had launched formulations of Bromhexine for the first time in India. Ipcas first APIs plant was commissioned at Ratlam in the year 1984 and also in the same period the second formulations plant was commissioned at Ratlam itself. Ipcas first APIs Plant for manufacturing of Chloroquine Phosphate was set up at Ratlam in the year 1986. As at 9th August 1988 again the company had changed its name to Ipca Laboratories Limited. Ipcas status was converted to a Public Limited Company in 24th March of the year 1993 and also in the same year the company had acquired Hoechst Indias formulations unit at Kandla.During the year 1994 Ipca had acquired API Plant from BDH Pharmaceuticals a subsidiary of E. Merck at Indore. In the year 1995 the modern formulations plant at Athal Silvassa came to line. After a year in 1996 the company had commissioned new API RD Centre at Mumbai. In 2000 received ISO 9001 certification for Athal Plant. The Company had incorporated two subsidiaries in Mauritius in the year of 2001 under the name of Solway Investments Ltd and Sundridge Management Ltd. during the year 2002 launched new domestic marketing division Intima to promote established brands with a focus on microinterior marketing and also in the same year incorporated wholly owned subsidiary in Brazil under the name of Laboratories Ipca Do Brasil Ltd. Launched new domestic marketing division in the year 2003 as Activa dedicated to Rheumatology Care. Forbes a leading US business magazine selected among its top 200 successful rising companies outside USA in the same year 2003. Commissioned new formulation plant at Silvassa in the year 2004. Forbes selected Ipca for the second consecutive year as one among the first 200 Best under a Billion Company in Asia. Innotech Pharma Limited was merged with Ipca in August of the year 2005. During the same year Ipca entered in to Joint Venture with Holley Group of China for marketing Artemisinin based API and Formulation. Joint Venture setup in SAIF Zone Sharjah U.A.E. and named as ACTIVA Pharmaceuticals FZC. Also acquired Cardiac brand ISORDIL from Wyeth Limited. Ipca had entered into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market in the year 2006. The Companys new plant at Dehradun was commenced operation from 5th May of the year 2006. As of January 2007 Ipca and Ranbaxy alliance had received U.S. FDA marketing approval for Atenolol Tablets. Ipcas New Biotech Research Development Unit was inaugurated at Mumbai in March of the same year 2007. Ipca had awarded by Forbes Inc. as one of the Best under a Billion Forbes Globals 200 Best Small Companies 2007. Ipca had received final approval from the US FDA for Metoclopramide tablets in June 2008. The Company had signed a partnership agreement with Clinton Foundation in July of the same year 2008. The Company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower latest instrumentation to upgrade and strengthen RD facilities. Also the company aims at developing newer drug delivery systems along with developing formulations for developed market and bioequivalence studies of the same.During the FY 2015 the Company acquired assets of formulations manufacturing unit situated at Plot No. T139 MIDCTarapur Palghar 401506. The Company has also acquired as a going concern on slump sale basis the High Potency Hormonal Oral Solid Dosage formulations manufacturing unit situated at Sector III Pithampur Dhar Madhya Pradesh together with its employees. This manufacturing unit has the approval of WHOGMP INVIMA Colombia and German.During the year 2015 the Company acquired joint management stake in M/s. Krebs Biochemicals Industries Ltd. a listed public limited company with fermentation based APIs manufacturing facilities situated at Visakhapatnam and Nellore Andhra Pradesh. The Company had also made public announcement of open offer to the public shareholders of the said company under SEBI Substantial Acquisition of Shares and Takeovers Regulations 2011.M/s. Krebs Biochemicals and Industries Ltd. became an associate company. No other company has become / ceased to be subsidiary or joint venture or associate company during the financial year 2015.During the year as a part of group reconstruction Ipca Laboratories UK Ltd. acquired the entire issued share capital of Onyx Scientific Ltd. UK from its wholly owned subsidiary Onyx Research Chemicals Ltd. U.K. on 25th March 2015 in lieu of capital dividend declared by the said company. Consequent to this Onyx Scientific Ltd. UK has become wholly owned subsidiary of Ipca Laboratories UK Ltd. from the said date. From the said date Onyx Research Chemicals Ltd. UK has ceased to trade and is in the process of being dissolved. The wholly owned subsidiary company Ipca Pharmaceuticals Shanghai Ltd. incorporated in the Peoples Republic of China is in the process of being voluntarily closed down.During the year 2016 the wholly owned subsidiary companies Ipca Pharmaceuticals Shanghai Ltd. incorporated in the Peoples Republic of China and National Druggists Pty Ltd. incorporated in the Republic of South Africa were voluntarily closed down. Onyx Research Chemicals Limited U.K. merged with its holding company Ipca Laboratories UK Ltd. Consequent to this Onyx Scientific Ltd. has now become wholly owned subsidiary of Ipca Laboratories U.K. Ltd. which in turn is the wholly owned subsidiary of the Company.During the year 2018 the Company acquired 100 share capital of Pisgah Labs Inc. a North Carolina Corporation Old Hendersonville Highway Pisgah Forest North Carolina USA through Ipca Pharmaceutical Inc. USA Companys wholly owned subsidiary and Onyx Scientific Ltd. U.K Onyx Companys wholly owned step down subsidiary for US 9.65 millions free of debt. Pisgah was founded as a contract manufacturer and developer of active pharmaceutical ingredients APIs and intermediates. During the year 201920 the Company acquired 100 paidup share capital of M/s. Ramdev Chemical Private Limited on 24th April 2019 and became its wholly owned subsidiary.During the year 2021 M/s. Trophic Wellness Private Ltd. got incorporated with the Company and became its subsidiary.During year 2022 Company acquired 26.57 of share capital of M/s. Lyka Labs Limited with the Promoters of the said Company. It made a Public Offer to acquire additional 26 Equity Shares of the said Company from its public shareholders where the Company now holds 26.58 of the equity share capital of the said Company.

Ipca Laboratories Ltd Share Price: ₹784.75 per share as on 23 Mar, 2023 12:49 PM
Ipca Laboratories Ltd Market Capitalisation: ₹21,712.01Cr as of today
Ipca Laboratories Ltd Revenue: ₹1,576.89Cr as on December 2022 (Q4 22)
Ipca Laboratories Ltd Net Profit: ₹107.84Cr as on December 2022 (Q4 22)
Ipca Laboratories Ltd Listing date: 11 Mar, 1994
Ipca Laboratories Ltd Chairperson Name: Premchand Godha
OrganisationIpca Laboratories Ltd
E-voting on sharesClick here to vote

Frequently Asked Questions

Ipca Laboratories Ltd(IPCALAB) share price today is ₹784.75 (last updated 23 Mar, 2023 at 12:49 PM)

  • Today’s highest price of Ipca Laboratories Ltd(IPCALAB) is ₹784.80.
  • Today’s lowest price of Ipca Laboratories Ltd(IPCALAB) is ₹784.60.
  • (last updated 23 Mar, 2023 at 12:49 PM)
Today’s traded volume of Ipca Laboratories Ltd(IPCALAB) is 73714.
Today’s market capitalisation of Ipca Laboratories Ltd(IPCALAB) is ₹21,712.01Cr.
Ipca Laboratories Ltd(IPCALAB)Price
52 Week High₹1095.00
52 Week Low₹767.50
  • (last updated 23 Mar, 2023 at 12:49 PM)
  • Ipca Laboratories Ltd(IPCALAB) share price is ₹784.75 (last updated 23 Mar, 2023 at 12:49 PM). It is down -28.33% from its 52 Week High price of ₹1095.00
    Ipca Laboratories Ltd(IPCALAB) share price is ₹784.75 (last updated 23 Mar, 2023 at 12:49 PM). It is up 2.25% from its 52 Week Low price of ₹767.50
    Ipca Laboratories Ltd(IPCALAB)Returns (%)
    1 Day Returns0.24%
    1 Month Returns-4.52%
    1 Year Returns-21.02%
    3 Year Returns14.48%
    5 Year Returns136.28%
    Ipca Laboratories Ltd(IPCALAB) share price is ₹784.75 and its price to earning (PE) is 37.84. A high PE ratio indicates that a share price is overvalued, or investors are expecting a high growth rate in the future.

    Indian stocks brokerage services are provided by INDmoney Private Limited. INDmoney Private Limited is carrying out the business of in respect to stock broking activities and also carries out the activities of depository participant. SEBI Registration No. INZ000305337 | SEBI Depository Participant Registration No. IN-DP-690-2022 Depository Participant ID: CDSL 12095500 | Trading and Clearing Member of NSE (90267, M70042) and BSE (6779)

    Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are exemplary and not recommendatory. Past performance is not indicative of future returns.